ALK and neoplasm: Nivolumab plus ipilimumab is approved in the United States as first-line treatment for adults with metastatic NSCLC with no EGFR/ALK aberrations and tumor PD-L1 expression ≥ 1%, and in Japan as first-line treatment regardless of tumor PD-L1 expression [12–14].